Global Markets

Boehringer expanding China CDMO plant

Boehringer Ingelheim has begun an expansion at its biomanufacturing facility in Shanghai as it looks to tap the “great potential in China.” The expansion at the site in Shanghai covers an additional bioreactor and will include the necessary utility and infrastructure to support GMP operations of two 2,000 L single use bioreactor manufacturing lines. When asked, the Germany-headquartered firm did not divulge further details on the specifics of the investment. Boehringer Ingelheim spent more than €70 million in the first-phase…

Lonza adding single-use capacity and 180 jobs at UK mammalian plant

Lonza will increase its mammalian process development and small-scale cGMP manufacturing capabilities through a multi-million pound investment at its Slough, UK site. Swiss contract development and manufacturing organization (CDMO) has told BioProcess Insider it is making a “multi-million pound investment” into its facility in Slough, UK. The site, located around 40km west of London, serves as Lonza’s center of excellence for mammalian biopharmaceutical process development and small-scale cGMP manufacturing, primarily for clinical phases. It also offers a range of analytical…

Beyond Humira: AbbVie looks to $35bn pipeline for future growth

With the world’s best-selling drug now facing direct biosimilar competition, AbbVie says it is confident its robust pipeline will deliver double-digit growth going forward. In 2018, the first biosimilar versions of Humira (adalimumab) were launched in Europe and other non-US markets. Meanwhile in October, Sandoz became the third firm to receive US Food and Drug Administration (FDA) approval for a Humira biosimilar. It is, therefore, fair to say sales of the world’s top selling drug – Humira clocked in sales…

Third Korean plant with 120,000L capacity back on for Celltrion

Celltrion has confirmed its third biomanufacturing plant will be constructed in Korea after assessing locations overseas. The facility will have 120,000 L of biologics capacity. Seo Jeong-jin, chairman of Korean drugmaker Celltrion, told investors at last year’s JP Morgan Healthcare Conference that plans laid down in 2016 to build a third biomanufacturing facility at its site in Songdo, Incheon had been scrapped in favor of a much larger facility overseas. But a year on and Celltrion has announced a U-turn.…

China’s biotech growth drives Pall center of excellence in Shanghai

Pall has established a Center of Excellence in Shanghai, China to service a biotech sector it says is worth $500 million and set to grow by double-digits. Bioprocessing vendor Pall has several centers of excellence (CoE) set up globally to showcase its biomanufacturing offerings and has now opened a center in Shanghai to service the Chinese market. “The goal of the CoE is to facilitate training and adoption of the advanced manufacturing technologies that will improve the productivity and robustness…

UK must avoid no-deal Brexit, says British pharma group

Crashing out of the European Union without a deal will be catastrophic, says the head of the Association of British Pharmaceutical Industry (ABPI) Mike Thompson.  However, the pharmaceutical industry is stockpiling medicines in preparation, he confirmed. As the UK braces itself for an unprecedented and potentially calamitous exit from the European Union (EU) on March 29th, firms including Pfizer, Merck & Co, and Sanofi, as well as UK-headquartered GlaxoSmithKline and AstraZeneca, have reportedly been stockpiling medicines. This was confirmed today by…

BMS $74bn Celgene deal to create ‘number one oncology franchise’

The acquisition of Celgene will boost Bristol-Myers Squibb’s commercial portfolio and clinical pipeline and create synergies of $2.5 billion, the firm says. The new year has started with an M&A bang, with pharma giant Bristol-Myers Squibb (BMS) announcing its intentions to acquire its immune-oncology partner Celgene in a deal valued at $74 billion (€65 billion). According to Giovanni Caforio, CEO of Bristol-Myers Squibb, four value areas drove the merger. The first is creating leading franchises in oncology, immunology and inflammation…

Avid: Balancing MAb capacity with industry’s growing needs

Monoclonal antibody (MAb) capacity remains roughly in balance with industry’s needs but firms should look to procure manufacturing services early to guarantee their projects, says CDMO Avid Bioservices. Twelve months ago, Peregrine Pharmaceuticals sold its internal monoclonal antibody (MAb) programs and became a pure contract development and manufacturing organization (CDMO) under the Avid Bioservices title. The CDMO has GMP facilities in Orange County, California offering biopharma firms both stainless steel and single-use biologics manufacturing services. As such, the firm spoke to…

Biotech patents: How to protect from IP threats

Thomas Wolski, partner at The Webb Law Firm, says biotech firms must file more patent applications earlier to overcome the threats of US legal uncertainty and unclear guidance. Uncertainty in US laws is one of the threats that the biotech industry has and continues to face when it comes to patents. And it seems like every patent case that the Supreme Court takes these days has a strong chance of reversing the Federal Circuit’s decision. To compound the problem, Congress’s…

Business must harness tech and innovation to thrive, says new Locate Bio CEO

Biotech must work at the frontiers of biology and innovation while operating in a highly regulated environment says business development expert Nick Staples, the new CEO of Locate Bio. UK-based cell and gene therapy firm Locate Bio has had a reshuffle at the top, hiring veteran biopharma business executive and industry analyst Dr Nick Staples as CEO. BioProcess Insider spoke with Staples to find out his vision for Locate Bio, and how best to manage the often conflicting business and…